NCT02086513View on ClinicalTrials.gov

Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT

PHASE1TerminatedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Graft Versus Host Disease

Interventions

DRUG

LDE225

Treatment with LDE225

Trial Locations (3)

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER

collaborator

Novartis

INDUSTRY